Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Harmony Biosciences Holdings Inc HRMY

Healthcare
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance... see more

Recent & Breaking News (NDAQ:HRMY)

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

PR Newswire August 14, 2023

Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates

GlobeNewswire August 1, 2023

HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM

PR Newswire August 1, 2023

HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY

PR Newswire July 27, 2023

Harmony Biosciences Announces Funding for Unique Community Initiatives Through its Patients and Progress at the Heart Awards Programs

PR Newswire July 25, 2023

HARMONY BIOSCIENCES ANNOUNCES PLANS TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF PITOLISANT IN PRADER-WILLI SYNDROME FOLLOWING POSITIVE END-OF-PHASE 2 MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION

PR Newswire July 20, 2023

HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS ON AUGUST 1, 2023

PR Newswire July 18, 2023

HARMONY BIOSCIENCES ANNOUNCES POSITIVE PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PRADER-WILLI SYNDROME AT SLEEP 2023

PR Newswire June 6, 2023

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 44th ANNUAL GLOBAL HEALTHCARE CONFERENCE

PR Newswire May 30, 2023

HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA

PR Newswire May 25, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harmony Biosciences Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 12, 2023

HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING

PR Newswire May 10, 2023

Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates

GlobeNewswire May 2, 2023

HARMONY BIOSCIENCES ANNOUNCES JEFFREY M. DAYNO, M.D. APPOINTED PRESIDENT & CHIEF EXECUTIVE OFFICER

PR Newswire April 24, 2023

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS ON MAY 2, 2023

PR Newswire April 20, 2023

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Harmony Biosciences (HRMY) Investors with Substantial Losses to Contact Firm, Firm Investigating Possible Securities Law Violations

Newsfile April 13, 2023

Harmony Biosciences Investigated For Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile April 10, 2023

Harmony Biosciences Investigated for Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Newsfile April 3, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harmony Biosciences Holdings, Inc. (HRMY) on Behalf of Investors

Business Wire March 30, 2023

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Harmony Biosciences (HRMY) Investors with Substantial Losses to Contact Firm, Firm Investigating Possible Securities Law Violations

Newsfile March 30, 2023